{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:52:34Z","timestamp":1772034754409,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcf.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:05:10Z","timestamp":1729019110000},"page":"1180-1184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Calibrating sweat chloride levels to CFTR activity via ETI effects on CF subjects with one or two F508DEL mutations"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4038-1392","authenticated-orcid":false,"given":"Jeffrey J.","family":"Wine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.09.004_bib0001","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.004_bib0002","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1073\/pnas.1914912117","article-title":"Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions","volume":"117","author":"Miller","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2024.09.004_bib0003","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1164\/rccm.200509-1377OC","article-title":"Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials","volume":"174","author":"Wilschanski","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0004","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1172\/JCI111385","article-title":"Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro","volume":"73","author":"Sato","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2024.09.004_bib0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1203\/00006450-198709000-00007","article-title":"Hyposecretion of beta-adrenergically induced sweating in cystic fibrosis heterozygotes","volume":"22","author":"Behm","year":"1987","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jcf.2024.09.004_bib0006","first-page":"511","article-title":"Variable reduction in beta-adrenergic sweat secretion in cystic fibrosis heterozygotes","volume":"111","author":"Sato","year":"1988","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0007","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201205-0922OC","article-title":"beta-adrenergic sweat secretion as a diagnostic test for cystic fibrosis","volume":"186","author":"Quinton","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0008","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jcf.2017.12.003","article-title":"Ratiometric sweat secretion optical test in cystic fibrosis, carriers and healthy subjects","volume":"17","author":"Bergamini","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.004_bib0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jcf.2021.10.005","article-title":"CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the beta-adrenergic sweat rate assay","volume":"21","author":"Pallenberg","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.004_bib0010","doi-asserted-by":"crossref","first-page":"e88564","DOI":"10.1371\/journal.pone.0088564","article-title":"A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor","volume":"9","author":"Char","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcf.2024.09.004_bib0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ppul.22945","article-title":"Sixty-five years since the New York heat wave: advances in sweat testing for cystic fibrosis","volume":"49","author":"Collie","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.09.004_bib0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.004_bib0013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jcf.2022.02.001","article-title":"How the sweat gland reveals levels of CFTR activity","volume":"21","author":"Wine","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.004_bib0014","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.09.004_bib0016","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0017","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0018","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0019","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0020","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2024.09.004_bib0021","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMc1213681","article-title":"Ivacaftor in a G551D homozygote with cystic fibrosis","volume":"369","author":"Harrison","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0022","unstructured":"CFTR2. The clinical and functional translation of CFTR (CFTR2) available at http:\/\/cftr2.org. 2023."},{"key":"10.1016\/j.jcf.2024.09.004_bib0023","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/ajrccm.154.5.8912731","article-title":"Cystic fibrosis","volume":"154","author":"Davis","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.004_bib0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1165\/rcmb.2001-0004OC","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2024.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1164\/rccm.201603-0459OC","article-title":"Sources of variation in sweat chloride measurements in cystic fibrosis","volume":"194","author":"Collaco","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T19:27:02Z","timestamp":1733254022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1569199324017120"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calibrating sweat chloride levels to CFTR activity via ETI effects on CF subjects with one or two F508DEL mutations","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}